Previsión

Comprar	0
Mantener	5
Vender	0

Noticias Ir al feed de noticias

Silverback Therapeutics hits 52-week high after strong price surge

Shares of Silverback Therapeutics reached a new 52-week high at $18.59, marking a year-over-year increase of 112.46%. The biotechnology company is benefiting from investor optimism, progress in its clinical pipeline, and a solid financial position. Analysts see further upside potential, while the company's market capitalization now stands at $1.81 billion. » Más en de.investing.com
Safety Shot completes acquisition of Yerbae Brands and expands product portfolio

Safety Shot, Inc. has completed the acquisition of Yerbae Brands Corp. through a court-approved plan of arrangement. Following the transaction, Safety Shot shareholders hold approximately 81.64% and former Yerbae shareholders about 18.36% of the merged company. Safety Shot also plans to expand its product portfolio to include nootropics and sleep aids, and has entered into a debt settlement agreement with Silverback Capital Corporation. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, SILVERBACK THERAP. -,0001 Aktie tuvo unos ingresos de 29,49 M € y un beneficio neto de -54,62 M €

(EUR)	jun 2026	YoY
Ingresos	29,49 M	121,16 %
Beneficio bruto	0	-
Beneficio neto	-54,62 M	43,44 %
EBITDA	-53,86 M	42,32 %

Datos fundamentales

Métrica	Valor
Capitalización bursátil	475,08 M €
Número de acciones	93,77 M
Máximo/mínimo de 52 semanas	6,51 € - 2,42 €
Dividendos	No
Beta	0,00
Ratio P/E	-2,70
Ratio PEG	0,03
Ratio P/B	46,75
Ratio P/S	5,00

Perfil de la empresa

Silverback Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das gewebebezogene Therapeutika für die Behandlung von chronischen Virusinfektionen, Krebs und anderen schweren Krankheiten entwickelt. Das Unternehmen bietet SBT8230 zur Behandlung chronischer Hepatitis-B-Virusinfektionen an, indem es eine antivirale Immunantwort durch gezielte TLR8-Aktivierung in der Leber auslöst. Silverback Therapeutics, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Seattle, Washington.

Nombre	SILVERBACK THERAP. -,0001 Aktie
CEO	Peter A. Thompson
Sede	Seattle, wa Estados Unidos
Sitio web	silverbacktx.com
Sector	Materiales
Industria	Productos químicos
Salida a bolsa	03/12/2020
Empleados	90